Company news
Septerna, Inc. (NASDAQ:SEPN) news
Every Septerna, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
August 25, 2026
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
August 10, 2026
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
June 8, 2026
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
May 11, 2026
Septerna to Present at Bank of America Securities Health Care Conference
May 5, 2026
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathy...
April 13, 2026
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
March 9, 2026
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines In...
March 1, 2026
Septerna to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2026
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
February 10, 2026
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
January 8, 2026
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Septerna to Participate in 8th Annual Evercore Healthcare Conference
November 25, 2025
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
November 10, 2025
Septerna to Participate in Upcoming Investor Conferences
November 3, 2025
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
September 29, 2025
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Alloste...
August 21, 2025
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
August 11, 2025
Septerna to Present at Jefferies Global Healthcare Conference
May 29, 2025
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
May 15, 2025
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
March 27, 2025
Septerna to Present at TD Cowen 45th Annual Health Care Conference
February 26, 2025
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
February 18, 2025
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
January 6, 2025
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 20, 2024
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
October 30, 2024